Hepatitis B virus infection and outcomes of TACE plus lenvatinib and PD-1 inhibitor therapy in unresectable hepatocellular carcinoma: a real-world propensity score-matched study.
Saved in:
| Title: | Hepatitis B virus infection and outcomes of TACE plus lenvatinib and PD-1 inhibitor therapy in unresectable hepatocellular carcinoma: a real-world propensity score-matched study. |
|---|---|
| Authors: | Su Y; Liver Transplantation Center and Hepato-Biliary and Pancreatic (HBP) Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China., Liang Y; Liver Transplantation Center and Hepato-Biliary and Pancreatic (HBP) Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China., Zhong D; Liver Transplantation Center and Hepato-Biliary and Pancreatic (HBP) Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China., Chen Y; Liver Transplantation Center and Hepato-Biliary and Pancreatic (HBP) Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China., Ma S; Liver Transplantation Center and Hepato-Biliary and Pancreatic (HBP) Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China., Wang M; Liver Transplantation Center and Hepato-Biliary and Pancreatic (HBP) Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China., Yang Q; Liver Transplantation Center and Hepato-Biliary and Pancreatic (HBP) Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China., Yan H; Liver Transplantation Center and Hepato-Biliary and Pancreatic (HBP) Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China., Huang X; Liver Transplantation Center and Hepato-Biliary and Pancreatic (HBP) Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. |
| Source: | Frontiers in immunology [Front Immunol] 2026 Apr 23; Vol. 17, pp. 1808956. Date of Electronic Publication: 2026 Apr 23 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2026.1808956 |
